OBJECTIVE: Our study evaluated the impaired health status of clinical trial patients with systemic lupus erythematosus (SLE) and explored the relationship between changes in fatigue and pain and their effect on overall health status. METHODS: Pooled treatment and placebo data from a phase Ib clinical trial of adults with moderate/severe SLE were analyzed. Measures included patient-reported Medical Outcome Study Short Form-36 Survey, Version 2 (SF-36v2), Fatigue Severity Scale, and numeric rating scales (NRS) for pain and global health assessment and clinician-reported global assessment of disease activity (MDGA). Disease burden was compared to the US general population. Health status of responders and nonresponders on pain or fatigue were compared. RESULTS: The sample included 161 patients with SLE, predominantly female (96%) and white (72%), with average age of 43 ± 11 years. Mean SF-36v2 component summary scores reflected overall problems with physical [physical component summary (PCS); 35.2 ± 9.7] and mental health (mental component summary; 40.9 ± 12.9). Patients with SLE had worse health status on all SF-36v2 subscales than the US general population and comparable age and sex norms (effect size -0.51 to -2.15). Pain and fatigue responders had greater improvements on SF-36v2 scores (bodily pain, physical functioning, social functioning, PCS), patient global health assessment NRS, and MDGA than nonresponders. There was moderate agreement in responder status, based on global assessments by patients and clinicians (68.1%), with some discrepancy between patients who were MDGA responders but patient assessment nonresponders (27.7%). CONCLUSION: Improvements in patient-reported pain or fatigue correlated with improvements in overall health. Patient assessments offer a unique perspective on treatment outcomes. Patient-reported outcomes add value in understanding clinical trial treatment benefits.
OBJECTIVE: Our study evaluated the impaired health status of clinical trial patients with systemic lupus erythematosus (SLE) and explored the relationship between changes in fatigue and pain and their effect on overall health status. METHODS: Pooled treatment and placebo data from a phase Ib clinical trial of adults with moderate/severe SLE were analyzed. Measures included patient-reported Medical Outcome Study Short Form-36 Survey, Version 2 (SF-36v2), Fatigue Severity Scale, and numeric rating scales (NRS) for pain and global health assessment and clinician-reported global assessment of disease activity (MDGA). Disease burden was compared to the US general population. Health status of responders and nonresponders on pain or fatigue were compared. RESULTS: The sample included 161 patients with SLE, predominantly female (96%) and white (72%), with average age of 43 ± 11 years. Mean SF-36v2 component summary scores reflected overall problems with physical [physical component summary (PCS); 35.2 ± 9.7] and mental health (mental component summary; 40.9 ± 12.9). Patients with SLE had worse health status on all SF-36v2 subscales than the US general population and comparable age and sex norms (effect size -0.51 to -2.15). Pain and fatigue responders had greater improvements on SF-36v2 scores (bodily pain, physical functioning, social functioning, PCS), patient global health assessment NRS, and MDGA than nonresponders. There was moderate agreement in responder status, based on global assessments by patients and clinicians (68.1%), with some discrepancy between patients who were MDGA responders but patient assessment nonresponders (27.7%). CONCLUSION: Improvements in patient-reported pain or fatigue correlated with improvements in overall health. Patient assessments offer a unique perspective on treatment outcomes. Patient-reported outcomes add value in understanding clinical trial treatment benefits.
Entities:
Keywords:
FATIGUE; PAIN; QUALITY OF LIFE; SIFALIMUMAB; SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: Laura Plantinga; Benjamin D Tift; Charmayne Dunlop-Thomas; S Sam Lim; C Barrett Bowling; Cristina Drenkard Journal: Arthritis Care Res (Hoboken) Date: 2018-08-27 Impact factor: 4.794
Authors: Jin-Shei Lai; Jennifer L Beaumont; Sally E Jensen; Karen Kaiser; David L Van Brunt; Amy H Kao; Shih-Yin Chen Journal: Clin Rheumatol Date: 2016-11-15 Impact factor: 2.980
Authors: Melissa S Y Thong; Mirjam A G Sprangers; Jeff A Sloan; Donald L Patrick; Ping Yang; Cornelis J F van Noorden Journal: Qual Life Res Date: 2014-11-12 Impact factor: 4.147
Authors: Vera Golder; Rangi Kandane-Rathnayake; Alberta Yik-Bun Hoi; Molla Huq; Worawit Louthrenoo; Yuan An; Zhan Guo Li; Shue Fen Luo; Sargunan Sockalingam; Chak Sing Lau; Mo Yin Mok; Aisha Lateef; Kate Franklyn; Susan Morton; Sandra Teresa V Navarra; Leonid Zamora; Yeong-Jian Wu; Laniyati Hamijoyo; Madelynn Chan; Sean O'Neill; Fiona Goldblatt; Mandana Nikpour; Eric Francis Morand Journal: Arthritis Res Ther Date: 2017-03-20 Impact factor: 5.156
Authors: Margarida Figueiredo-Braga; Caleb Cornaby; Miguel Bernardes; Marta Figueiredo; Cristina Dos Santos Mesquita; Lúcia Costa; Brian D Poole Journal: PLoS One Date: 2018-04-16 Impact factor: 3.240
Authors: Laura C Plantinga; Grace Xu; Courtney Hoge; Ann Vandenberg; Charmayne Dunlop-Thomas; Brian D Jones; Jeremy Johnson; Cristina Drenkard; S Sam Lim; C Barrett Bowling Journal: Arthritis Care Res (Hoboken) Date: 2021-07-19 Impact factor: 5.178
Authors: Margarida Figueiredo-Braga; Caleb Cornaby; Alice Cortez; Miguel Bernardes; Georgina Terroso; Marta Figueiredo; Cristina Dos Santos Mesquita; Lúcia Costa; Brian D Poole Journal: Medicine (Baltimore) Date: 2018-07 Impact factor: 1.889